Neurotrophic Options — Stacking Protocols
CAUTION: Dihexa prodrug FAILED Phase 2/3 trials. Cerebrolysin has clinical data. Combined for synaptogenesis, neuroplasticity, and cognitive repair.
Overview
CRITICAL WARNING: Dihexa has ZERO human clinical trials. Fosgonimeton (pharmaceutical prodrug) FAILED all Phase 2/3 trials (ACT-AD, LIFT-AD Sept 2024, SHAPE). Development paused Sept 2024. Cancer risk: c-Met is an oncogene. Cerebrolysin has clinical data for neuroregeneration. This combination has no validated evidence for efficacy or safety.
Indications
- Synaptogenesis, neuroplasticity, and cognitive repair (CEREBROLYSIN has evidence; DIHEXA is preclinical only)
- Synergistic peptide combination therapy (UNVALIDATED)
- Multi-pathway optimization (EXPERIMENTAL)
Mechanism of Action
Synaptogenesis, neuroplasticity, and cognitive repair
Dosing
| Compound | Dose | Frequency | Notes |
|---|---|---|---|
| Dihexa + Cerebrolysin | See dosing notes | As per protocol | ⚠️ Dihexa dosing is NOT clinically validated |
Evidence Grade
GRADE D
Safety & Contraindications
- ❌ DIHEXA: ZERO human clinical trials - ALL data is preclinical
- ❌ FOSGONIMETON (Dihexa prodrug) FAILED all Phase 2/3 trials - development paused
- ⚠️ CANCER RISK: HGF/c-Met is an oncogene pathway - theoretical tumor/metastasis risk
- ⚠️ NO VALIDATED DOSING for Dihexa - all 'clinical dosing' is user-reported
- Cerebrolysin requires medical setting for IV/IM administration
- Consult healthcare provider before combining multiple peptides